Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

20 Oct 2022

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to Signaling Pathways in Disease
Share to Sirtuins and Resveratrol in Medicine

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 36273926
DOI: 10.1016/j.ygyno.2022.08.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaPMID 36273926Read ↗

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancerSemantic proximity Read ↗

Ovarian cancer: emerging molecular-targeted therapiesSemantic proximity Read ↗

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Semantic proximity Read ↗

Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary ReviewSemantic proximity Read ↗

Untitled literature recordSemantic proximity Read ↗

Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma.Semantic proximity Read ↗

A multi-omic single-cell landscape of human gynecologic malignanciesSemantic proximity Read ↗

Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectivesSemantic proximity Read ↗

Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological featuresSemantic proximity Read ↗

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivorsSemantic proximity Read ↗

Ovarian Clear Cell Carcinoma: Genomic Characterization, Pathogenesis and Targeted TherapySemantic proximity Read ↗

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.